As previously mentioned for some reason I didn't hear the question on the 2nd generation PI so take this as a general comment. I've noticed Dan Welch being very closed lipped on events with both positive and negative outcomes so I would caution reading too much into that.
It comes up towards the very end of the CC just before the 37 minute mark. Dan Welch says a few different things but the ultimate point is effectively "no comment." I hear what you're saying but I don't see why he couldn't at least give general guidance that the Phase 1 trial would likely commence 4Q10 or 1Q11 or some other general timeline if the 2nd gen HCV PI were at least somewhat close to the clinic. To give no rough timeline whatsoever leads me to believe they are not close or there is some other issue. I could be wrong of course. We shall see.
Market Data 
Markets 
AI
